

In the Claims

A complete set of claims is provided below, with amendments indicated by strikethrough text (for deletions) and underlining (for insertions). Please amend the claims as follows:

1-38. (Canceled)

1 29. (Currently amended) An isolated nucleic acid molecule encoding a polypeptide having a CUB domain, wherein said polypeptide has anti-proliferative activity and consists ~~consisting~~ essentially of the amino acid sequence of SEQ ID NO:26.

2 40. (Previously presented) An isolated nucleic acid molecule encoding a polypeptide having a CUB domain, said polypeptide consisting essentially of the amino acid sequence of SEQ ID NO:27.

3 41. (Previously presented) An isolated nucleic acid molecule according to claim ²40, consisting essentially of the nucleotide sequence of SEQ ID NO:28.

42-43. (Canceled)

4 44. (Previously presented) An expression vector comprising an isolated nucleic acid molecule according to claim ²39 or claim ²40.

45. (Canceled)

^{An isolated}
5 46. (Original) ~~A~~ host cell transformed or transfected with an expression vector according to claim ~~44~~. ⁷

47-55. (Canceled)

6. 36. (Currently amended) An isolated nucleic acid molecule encoding a polypeptide that has anti-proliferative activity and consists ~~consisting~~ essentially of the amino acid sequence of SEQ ID NO:26 for use as a medicament.

57-72. (canceled)

7. 73. (previously presented) A pharmaceutical composition comprising the isolated nucleic acid molecule according to any of claims 39 to 41, together with a pharmaceutically acceptable carrier, diluent or excipient therefor.